The drugmaker settled a case in which the Justice Dept. charged that it markets Aranesp — an anemia drug — for unapproved uses. Amgen (AMGN) will pay a $612 mil civil settlement, $136 mil in criminal fines and a $14 mil forfeiture, the Associated Press reported. The U.S. attorney's office says the company will also admit to misbranding. Amgen says it entered a conditional guilty plea to a misdemeanor count of misbranding Aranesp. Shares fell 0.2% to 89.29.
- Crime & Justice
- Politics & Government